- -

Phase II clinical trial with gemcitabine and paclitaxel sequential monotherapy as first-line treatment for advanced non-small-cell lung cancer (SLCG 01-04)

RiuNet: Institutional repository of the Polithecnic University of Valencia

Share/Send to

Cited by

Statistics

Phase II clinical trial with gemcitabine and paclitaxel sequential monotherapy as first-line treatment for advanced non-small-cell lung cancer (SLCG 01-04)

Show full item record

Iranzo, V.; Sirera Pérez, R.; Carrato, A.; Cabrera, A.; Jantus, E.; Guijarro, R.; Sanmartín, E.... (2011). Phase II clinical trial with gemcitabine and paclitaxel sequential monotherapy as first-line treatment for advanced non-small-cell lung cancer (SLCG 01-04). Clinical & Translational Oncology. 13(6):411-418. doi:10.1007/s12094-011-0675-0

Por favor, use este identificador para citar o enlazar este ítem: http://hdl.handle.net/10251/65054

Files in this item

Item Metadata

Title: Phase II clinical trial with gemcitabine and paclitaxel sequential monotherapy as first-line treatment for advanced non-small-cell lung cancer (SLCG 01-04)
Author: Iranzo, Vega Sirera Pérez, Rafael Carrato, Alfredo Cabrera, Andrea Jantus, Eloísa Guijarro, Ricardo Sanmartín, Elena Blasco, Ana Gil, Mireia Gómez Aldaraví, Lorenzo González Larriba, José Luis Massuti, Bertomeu Velasco, Amalia Provencio, Mariano Rosell, Rafael Camps, Carlos
UPV Unit: Universitat Politècnica de València. Departamento de Biotecnología - Departament de Biotecnologia
Issued date:
Abstract:
[EN] Background: In advanced-stage (IIIB or IV) non-small-cell lung cancer (NSCLC), combination chemotherapy has demonstrated response rates of 20% and a 1-year survival rate of 30%. We conducted a multicentre, open-label, ...[+]
Subjects: EGFR , HTERT , Non-small-cell lung cancer , Pharmacogenomics , Sequential monotherapy , VEGF , Epidermal growth factor receptor , Gemcitabine , Paclitaxel , Telomerase reverse transcriptase , Vasculotropin , Adult , Advanced cancer , Aged , Alopecia , Anemia , Anorexia , Article , Blood toxicity , Cancer staging , Cancer survival , Chemotherapy induced emesis , Clinical article , Controlled study , Diarrhea , Dose response , Drug dose reduction , Drug dose sequence , Drug efficacy , Drug hypersensitivity , Drug tolerability , Drug withdrawal , Enzyme blood level , Fatigue , Febrile neutropenia , Female , Heart disease , Human , Lung non small cell cancer , Male , Monotherapy , Multicenter study , Multiple cycle treatment , Mutational analysis , Nausea , Neuropathy , Neutropenia , Oncogene K ras , Overall survival , Paresthesia , Peripheral neuropathy , Phase 2 clinical trial , Primary health care , Prognosis , Protein blood level , Quality of life , Sensory neuropathy , Survival time , Thrombocytopenia , Treatment duration , Treatment response , Adenocarcinoma , Antineoplastic Combined Chemotherapy Protocols , Carcinoma, Large Cell , Carcinoma, Non-Small-Cell Lung , Carcinoma, Squamous Cell , Deoxycytidine , Humans , Lung Neoplasms , Lymphatic Metastasis , Middle Aged , Neoplasm Recurrence, Local , Survival Rate , Treatment Outcome
Copyrigths: Cerrado
Source:
Clinical & Translational Oncology. (issn: 1699-048X )
DOI: 10.1007/s12094-011-0675-0
Publisher:
Springer
Publisher version: https://dx.doi.org/10.1007/s12094-011-0675-0
Type: Artículo

References

Rapp E, Pater JL, Willan A et al (1988) Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer: report of a Canadian multicenter randomized trial. J Clin Oncol 6:633–641

Schiller JH, Harrington D, Belani CP et al (2002) Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346:92–98

Pfister DG, Johnson DH, Azzoli CG et al (2004) American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 22:330–353 [+]
Rapp E, Pater JL, Willan A et al (1988) Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer: report of a Canadian multicenter randomized trial. J Clin Oncol 6:633–641

Schiller JH, Harrington D, Belani CP et al (2002) Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346:92–98

Pfister DG, Johnson DH, Azzoli CG et al (2004) American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 22:330–353

(1995) Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ 311:899–909

Rixe O, Gatineau M, Jauffret E et al (2005) Sequential administration of docetaxel followed by cisplatin-vindesine: a pilot study in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). Bull Cancer 92:E1–E6

Norton L, Day R (1991) Potential innovations in scheduling of cancer chemotherapy. Important Adv Oncol 57–72

Grossi F, Aita M, Follador A et al (2007) Sequential, alternating, and maintenance/consolidation chemotherapy in advanced non-small cell lung cancer: a review of the literature. Oncologist 12:451–464

Poon D, Foo KF, Chew L et al (2006) Phase II trial of gemcitabine and cisplatin sequentially administered in Asian patients with unresectable or metastatic non-small cell lung cancer. Ann Acad Med Singapore 35:33–37

Hirsh V, Latreille J, Kreisman H et al (2005) Sequential therapy with Vinorelbine followed by Gemcitabine in patients with metastatic non small cell lung cancer (NSCLC), performance status (PS) 2, or elderly with comorbidities: a multicenter phase II trial. Lung Cancer 49:117–123

Hesketh PJ, Chansky K, Lau DH et al (2006) Sequential vinorelbine and docetaxel in advanced non-small cell lung cancer patients age 70 and older and/or with a performance status of 2: a phase II trial of the Southwest Oncology Group (S0027). J Thorac Oncol 1:537–544

Marsland TA, Garfield DH, Khan MM et al (2005) Sequential versus concurrent paclitaxel and carboplatin for the treatment of advanced non-small cell lung cancer in elderly patients and patients with poor performance status: results of two Phase II, multicenter trials. Lung Cancer 47:111–120

Martoni AA, Bernardi A, Quercia S (2006) Trastuzumab plus estrogen suppression as salvage treatment in a case of liver failure due to metastatic breast cancer. Anticancer Res 26:3739–3744

Camps C, Sirera R, Bremnes RM et al (2006) Quantification in the serum of the catalytic fraction of reverse telomerase: a useful prognostic factor in advanced non-small cell lung cancer. Anticancer Res 26:4905–4909

Camps C, Sirera R, Bremnes R et al (2005) Is there a prognostic role of K-ras point mutations in the serum of patients with advanced non-small cell lung cancer? Lung Cancer 50:339–346

Crowley J, Pauler DA (2006) Handbook of statistics in clinical oncology. Chapman & Hall/CRC, Boca Raton, FL, pp 289–333

Bonomi P, Kim K, Fairclough D et al (2000) Comparison of survival and quality of life in advanced non small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial. J Clin Oncol 18:623–631

Le Chevalier T, Brisgand D, Douillard JY et al (1994) Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients. J Clin Oncol 12:360–367

Day RS (1986) Treatment sequencing, asymmetry, and uncertainty: protocol strategies for combination chemotherapy. Cancer Res 46:3876–3885

Feliu J, Martin G, Lizon J et al (2001) Sequential therapy in advanced non-small-cell lung cancer with weekly paclitaxel followed by cisplatingemcitabine-vinorelbine. A phase II study. Ann Oncol 12:1369–1374

Edelman MJ, Clark JI, Chansky K et al (2004) Randomized phase II trial of sequential chemotherapy in advanced non-small cell lung cancer (SWOG 9806): carboplatin/gemcitabine followed by paclitaxel or cisplatin/vinorelbine followed by docetaxel. Clin Cancer Res 10:5022–5026

Manegold C, Thatcher N, Kortsik C et al (2005) A phase II/III randomized study in advanced nonsmall cell lung cancer (NSCLC) with first line combination versus sequential gemcitabine (G) and docetaxel (D): update on quality of life (QoL), toxicity, and costs. J Clin Oncol 23(16S):7057

Ramanathan RK, Belani CP (1997) Chemotherapy for advanced non-small cell lung cancer: past, present, and future. Semin Oncol 24:440–454

Gatzemeier U, Shepherd FA, Le Chevalier T et al (1996) Activity of gemcitabine in patients with non-small cell lung cancer: a multicentre, extended phase II study. Eur J Cancer 32A:243–248

Cerny T, Kaplan S, Pavlidis N et al (1994) Docetaxel (Taxotere) is active in nonsmall-cell lung cancer: a phase II trial of the EORTC Early Clinical Trials Group (ECTG). Br J Cancer 70:384–387

Viens P, Palangie T, Janvier M et al (1999) Firstline high-dose sequential chemotherapy with rGCSF and repeated blood stem cell transplantation in untreated inflammatory breast cancer: toxicity and response (PEGASE 02 trial). Br J Cancer 81:449–456

Wandt H, Birkmann J, Denzel T et al (1999) Sequential cycles of high-dose chemotherapy with dose escalation of carboplatin with or without paclitaxel supported by G-CSF mobilized peripheral blood progenitor cells: a phase I/II study in advanced ovarian cancer. Bone Marrow Transplant 23:763–770

Bonadonna G (1992) Evolving concepts in the systemic adjuvant treatment of breast cancer. Cancer Res 52:2127–2137

Delbaldo C, Michiels S, Syz N et al (2004) Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-smallcell lung cancer: a meta-analysis. JAMA 292: 470–484

Gralla RJ, Thatcher N (2004) Quality-of-life assessment in advanced lung cancer: considerations for evaluation in patients receiving chemotherapy. Lung Cancer 46[Suppl 2]:S41–S47

Spano JP, Lagorce C, Atlan D et al (2005) Impact of EGFR expression on colorectal cancer patient prognosis and survival. Ann Oncol 16:102–108

Selvaggi G, Novello S, Torri V et al (2004) Epidermal growth factor receptor overexpression correlates with a poor prognosis in completely resected non-small-cell lung cancer. Ann Oncol 15:28–32

Bremnes RM, Camps C, Sirera R (2006) Angiogenesis in non-small cell lung cancer: the prognostic impact of neoangiogenesis and the cytokines VEGF and bFGF in tumours and blood. Lung Cancer 51:143–158

Laack E, Kohler A, Kugler C et al (2002) Pretreatment serum levels of matrix metalloproteinase-9 and vascular endothelial growth factor in non-small-cell lung cancer. Ann Oncol 13:1550–1557

[-]

This item appears in the following Collection(s)

Show full item record